Hepatic arterial infusion chemotherapy via arterial infusion port combined with Atezolizumab and Bevacizumab for conversion therapy of advanced hepatocellular carcinoma - a case report

Sep 30, 2026

Upload by Rhys

Combination regimens with multiple mechanisms are increasingly explored for advanced hepatocellular carcinoma (HCC), yet conversion therapy using hepatic arterial infusion chemotherapy (HAIC) together with Atezolizumab and Bevacizumab has rarely been described. A 58-year-old man underwent HAIC via an implanted arterial infusion port catheter and received four cycles of FOLFOX-HAIC with both agents, followed by resection. After 17 months, no recurrence was reported and progression-free survival reached 21 months, supporting feasibility and potential efficacy.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages8

Reading Time20 min

AccessFree to download

Abstract

Background

Case description

Conclusion

Introduction

Liu et al. Discover Oncology (2026) 17:33 [https://doi.org/10.1007/s12672-025-04132-4](https://doi.org/10.1007/s12672-025-04132-4) Discover Oncology CASE REPORT Open Access Hepatic arterial infusion chemotherapy via arterial infusion port combined with Atezolizumab and Bevacizumab for conversion therapy of advanced hepatocellular carcinoma: a case report Jiaxuan Liu 1†, Zichun Zhao 1†, Yulong Tian 1*† and Haibo Shao 1*† | †Jiaxuan Liu and Zichun Zhao have contributed equally to this work. | | --- | | †Yulong Tian and Haibo Shao have contributed equally to this work. | *Correspondence: Yulong Tian [tianyulong@cmu.edu.cn](tianyulong@cmu.edu.cn)[ ](tianyulong@cmu.edu.cn)Haibo Shao [haiboshao@aliyun.com](haiboshao@aliyun.com)[ ](haiboshao@aliyun.com)1Department of Interventional Radiology, The First Hospital of China Medical University, Liaoning 110000, China Abstract Background The effectiveness of combination therapies with multiple mechanisms of action in treating advanced hepatocellular carcinoma (HCC) has been highlighted by the observed synergistic antitumor effects. The conversion therapy of hepatic arterial infusion chemotherapy (HAIC) with Atezolizumab and Bevacizumab in HCC has rarely been reported. This case reports a conversion therapy of HAIC combined with Atezolizumab and Bevacizumab for hepatocellular carcinoma. Case description A 58-year-old male patient, with CT diagnosed as a parenchymal liver mass 1 week before admission, suggesting consideration of hepatocellular carcinoma. Further magnetic resonance imaging (MRI) of the liver in our hospital revealed a huge tumor in the right lobe of the liver with large vascular invasion, suggesting a malignant lesion. We performed the HAIC via the implanted arterial infusion port catheter in the right groin region. The patient achieved a complete response after four cycles of FOLFOX-HAIC combined with Atezolizumab and Bevacizumab and then underwent surgical resection of the intrahepatic lesion following conversion therapy, with no recurrence at 17 months after surgery, and this status has continued until the submission of this article. Progression-free survival was 21 months. Conclusion The combined approach of FOLFOX-HAIC via transarterial infusion port with Atezolizumab and Bevacizumab showed promising results with the potential to improve treatment compliance in certain patients while providing the opportunity for radical surgical resection of advanced HCC. Given these encouraging results, further research on this combination treatment regimen is necessary, and accumulation of further experience is needed to better understand its efficacy and potential wider use in the clinical setting. Keywords Hepatocellular carcinoma, Hepatic arterial infusion chemotherapy, Arterial infusion port, Targeted therapy, Immunotherapy, Conversion therapy, Case report © The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by-nc-nd/4.0/. 1 Introduction Hepatocellular carcinoma

FAQs

What treatment approach was used in this case report?

The patient received HAIC through an implanted arterial infusion port catheter, using four cycles of FOLFOX-HAIC combined with Atezolizumab and Bevacizumab, followed by surgical resection after conversion therapy.

What clinical outcome was observed after conversion therapy?

The case described complete response after four cycles, no recurrence at 17 months after surgery, and a reported progression-free survival of 21 months.

Why might the arterial infusion port method be beneficial?

Administering FOLFOX-HAIC via the arterial port avoided multiple punctures and femoral catheterization, shortened procedure time, and reduced treatment-related complications and medical costs while improving patient comfort.

Sep 30, 2026

Upload by Rhys